GlobeNewswire: VYNE Therapeutics Inc. Contains the last 10 of 151 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:48:17ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/19/2848504/0/en/VYNE-Therapeutics-to-Participate-in-the-H-C-Wainwright-2nd-Annual-Autoimmune-Inflammatory-Disease-Virtual-Conference.html?f=22&fvtc=4&fvtv=41967VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference2024-03-19T12:00:00Z<![CDATA[BRIDGEWATER, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, and Dr. Iain Stuart, Chief Scientific Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (Skin Diseases, Conditions and Disorders) being held on Thursday, March 28, 2024.]]>https://www.globenewswire.com/news-release/2024/02/29/2837916/0/en/VYNE-Reports-2023-Fourth-Quarter-and-Year-End-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=41967VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update2024-02-29T13:00:00Z<![CDATA[BRIDGEWATER, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.]]>https://www.globenewswire.com/news-release/2024/02/27/2835971/0/en/VYNE-Therapeutics-to-Present-Results-of-the-Phase-1b-Trial-for-VYN201-at-the-2024-Global-Vitiligo-Foundation-Annual-Scientific-Symposium.html?f=22&fvtc=4&fvtv=41967VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium2024-02-27T13:00:00Z<![CDATA[BRIDGEWATER, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Dr. Iain Stuart, Chief Scientific Officer of the Company, will deliver an oral presentation featuring positive data from the Phase 1b trial of VYN201 in vitiligo at the 2024 Global Vitiligo Foundation Annual Scientific Symposium taking place in San Diego on March 7, 2024.]]>https://www.globenewswire.com/news-release/2024/02/21/2832694/0/en/VYNE-Therapeutics-to-Participate-in-the-TD-Cowen-44th-Annual-Health-Care-Conference.html?f=22&fvtc=4&fvtv=41967VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference2024-02-21T13:00:00Z<![CDATA[BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Massachusetts, on March 4, 2024. Management will also be available for 1-on-1 meetings with investors.]]>https://www.globenewswire.com/news-release/2024/01/10/2807052/0/en/VYNE-Therapeutics-Announces-Positive-Biomarker-Data-from-Successful-Phase-1b-Trial-of-VYN201-for-the-Treatment-of-Vitiligo.html?f=22&fvtc=4&fvtv=41967VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo2024-01-10T13:00:00Z<![CDATA[BRIDGEWATER, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced new biomarker data from the previously completed Phase 1b trial in patients with nonsegmental vitiligo. The data show that BET inhibitor, VYN201, had a positive effect on multiple disease-associated biomarkers.]]>https://www.globenewswire.com/news-release/2024/01/03/2803242/0/en/VYNE-Therapeutics-Appoints-Christine-Borowski-Ph-D-to-its-Board-of-Directors.html?f=22&fvtc=4&fvtv=41967VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors2024-01-03T13:00:00Z<![CDATA[BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024.]]>https://www.globenewswire.com/news-release/2023/11/13/2778962/0/en/VYNE-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=41967VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update2023-11-13T12:45:00Z<![CDATA[Transformative capital raise of $88.2 million from leading healthcare investors provides funding for BET inhibitor programs through the end of 2025]]>https://www.globenewswire.com/news-release/2023/11/07/2775064/0/en/VYNE-Therapeutics-to-Host-Virtual-R-D-Day-Event-on-November-9-2023.html?f=22&fvtc=4&fvtv=41967VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 20232023-11-07T13:00:00Z<![CDATA[Event will highlight VYN201 Phase 1b trial results, VYN202 preclinical data and VYNE’s clinical development plans]]>https://www.globenewswire.com/news-release/2023/11/01/2771744/0/en/VYNE-Therapeutics-Announces-Closing-of-Previously-Announced-Private-Placement-of-88-2-Million.html?f=22&fvtc=4&fvtv=41967VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million 2023-11-01T20:15:00Z<![CDATA[Transformative capital raise to fund VYNE’s BET inhibitor programs through the end of 2025 Transformative capital raise to fund VYNE’s BET inhibitor programs through the end of 2025]]>https://www.globenewswire.com/news-release/2023/10/30/2769061/0/en/VYNE-Therapeutics-Reports-Positive-Results-from-Preclinical-Models-for-Oral-BD2-Selective-BET-Inhibitor-VYN202.html?f=22&fvtc=4&fvtv=41967VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN2022023-10-30T11:20:00Z<![CDATA[BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced new preclinical data showing the positive effect of its oral small molecule BD2-selective BET inhibitor, VYN202, in preclinical models of psoriasis and rheumatoid arthritis.]]>